Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)
Sponsor: Merck Sharp & Dohme LLC
Summary
This will be a randomized, placebo-controlled, parallel-group, multi-site, double-blind trial of elpipodect compared with placebo, using Risperidone as an active control. The participants will be adult subjects experiencing an acute episode of schizophrenia, according to the criteria specified in the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-5). This study will be up to 7 weeks in duration, with up to 7 site visits for each participant. The study will consist of a Screening/tapering period (up to one week long), a 4-week treatment period, and a 14-day follow-up period. The primary objective will be to assess symptoms of schizophrenia at 4 weeks, and to assess safety and tolerability during treatment and post-treatment follow-up. The secondary objective will be to assess the severity of schizophrenia at 4 weeks. The primary hypothesis is that elpipodect is superior to placebo in reducing the overall symptoms of schizophrenia as assessed by the mean change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score after 4 weeks of treatment.
Official title: A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of MK-8189 Using Risperidone as an Active Control in Subjects Experiencing an Acute Episode of Schizophrenia
Key Details
Gender
All
Age Range
18 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
224
Start Date
2017-03-08
Completion Date
2018-01-09
Last Updated
2026-04-29
Healthy Volunteers
No
Conditions
Interventions
Elpipodect
Oral CR tablets (4 mg) administered QD at the following dose strengths: 4 mg (1 tablet); 8 mg (2 tablets); 12 mg (3 tablets)
Risperidone
Oral capsules (2 mg) administered QD at the following dose strengths: 2 mg (1 capsule); 4 mg (2 capsules); 6 mg (3 capsules)
Placebo matching MK-8189
Oral placebo tablet(s) matching the MK-8189 tablet, administered QD.
Placebo matching risperidone
Oral placebo capsule(s) matching the risperidone capsule, administered QD.
Locations (28)
Woodland International Research Group, LLC ( Site 0001)
Little Rock, Arkansas, United States
Woodland Research Northwest, LLC ( Site 0014)
Rogers, Arkansas, United States
CITRIALS ( Site 0013)
Bellflower, California, United States
Comprehensive Clinical Development ( Site 0049)
Cerritos, California, United States
Collaborative Neuroscience Network, LLC ( Site 0057)
Garden Grove, California, United States
Behavioral Research Specialists, LLC ( Site 0006)
Glendale, California, United States
Synergy East ( Site 0003)
Lemon Grove, California, United States
NRC Research Institute ( Site 0043)
Orange, California, United States
CNRI - Los Angeles, LLC ( Site 0026)
Pico Rivera, California, United States
Artemis Institute for Clinical Research ( Site 0027)
San Diego, California, United States
Schuster Medical Research Institute ( Site 0032)
Sherman Oaks, California, United States
Collaborative Neuroscience Network, LLC ( Site 0046)
Torrance, California, United States
Larkin Community Hospital Behavioral Health Services ( Site 0020)
Hollywood, Florida, United States
Clinical Research Centers of America, LLC ( Site 0038)
Oakland Park, Florida, United States
Aspire Health Partners ( Site 0016)
Orlando, Florida, United States
Radiant Research - Atlanta ( Site 0008)
Atlanta, Georgia, United States
Atlanta Center For Medical Research ( Site 0056)
Atlanta, Georgia, United States
Alexian Center for Psychiatric Research ( Site 0015)
Hoffman Estates, Illinois, United States
Lake Charles Clinical Trials, LLC ( Site 0040)
Lake Charles, Louisiana, United States
CBH Health, LLC ( Site 0022)
Gaithersburg, Maryland, United States
Precise Research Centers ( Site 0018)
Flowood, Mississippi, United States
Psych Care Consultants Research ( Site 0025)
St Louis, Missouri, United States
St. Louis Clinical Trials, LLC ( Site 0012)
St Louis, Missouri, United States
Altea Research Institute ( Site 0017)
Las Vegas, Nevada, United States
Radiant Research -CliniLabs ( Site 0037)
New York, New York, United States
Midwest Clinical Research Unit ( Site 0041)
Dayton, Ohio, United States
InSite Clinical Research ( Site 0033)
DeSoto, Texas, United States
Pillar Clinical Research, LLC ( Site 0004)
Richardson, Texas, United States